Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Structural mapping of oligomeric intermediates in an amyloid assembly pathway.

Karamanos TK, Jackson MP, Calabrese AN, Goodchild SC, Cawood EE, Thompson GS, Kalverda AP, Hewitt EW, Radford SE.

Elife. 2019 Sep 25;8. pii: e46574. doi: 10.7554/eLife.46574.

2.

A new era for understanding amyloid structures and disease.

Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE.

Nat Rev Mol Cell Biol. 2018 Dec;19(12):755-773. doi: 10.1038/s41580-018-0060-8. Review.

3.

Conformational flexibility within the nascent polypeptide-associated complex enables its interactions with structurally diverse client proteins.

Martin EM, Jackson MP, Gamerdinger M, Gense K, Karamonos TK, Humes JR, Deuerling E, Ashcroft AE, Radford SE.

J Biol Chem. 2018 Jun 1;293(22):8554-8568. doi: 10.1074/jbc.RA117.001568. Epub 2018 Apr 12.

4.

A peptide-display protein scaffold to facilitate single molecule force studies of aggregation-prone peptides.

Doherty CPA, Young LM, Karamanos TK, Smith HI, Jackson MP, Radford SE, Brockwell DJ.

Protein Sci. 2018 Jul;27(7):1205-1217. doi: 10.1002/pro.3386. Epub 2018 Mar 10.

5.

Why are Functional Amyloids Non-Toxic in Humans?

Jackson MP, Hewitt EW.

Biomolecules. 2017 Sep 22;7(4). pii: E71. doi: 10.3390/biom7040071. Review.

6.

How to consider animal data in tDCS safety standards.

Jackson MP, Bikson M, Liebetanz D, Nitsche M.

Brain Stimul. 2017 Nov - Dec;10(6):1141-1142. doi: 10.1016/j.brs.2017.08.004. Epub 2017 Aug 18. No abstract available.

7.

Toward comprehensive tDCS safety standards.

Jackson MP, Bikson M, Liebetanz D, Nitsche M.

Brain Behav Immun. 2017 Nov;66:413. doi: 10.1016/j.bbi.2017.08.007. Epub 2017 Aug 9. No abstract available.

8.

Safety parameter considerations of anodal transcranial Direct Current Stimulation in rats.

Jackson MP, Truong D, Brownlow ML, Wagner JA, McKinley RA, Bikson M, Jankord R.

Brain Behav Immun. 2017 Aug;64:152-161. doi: 10.1016/j.bbi.2017.04.008. Epub 2017 Apr 17.

9.

Animal models of transcranial direct current stimulation: Methods and mechanisms.

Jackson MP, Rahman A, Lafon B, Kronberg G, Ling D, Parra LC, Bikson M.

Clin Neurophysiol. 2016 Nov;127(11):3425-3454. doi: 10.1016/j.clinph.2016.08.016. Epub 2016 Sep 10. Review.

10.

Cellular proteostasis: degradation of misfolded proteins by lysosomes.

Jackson MP, Hewitt EW.

Essays Biochem. 2016 Oct 15;60(2):173-180. Review.

11.

Posttraumatic Stress Disorder and Stressful Life Events Among Rural Women With HIV Disease.

Kemppainen JK, MacKain S, Alexander M, Reid P, Jackson MP.

J Assoc Nurses AIDS Care. 2017 Mar - Apr;28(2):216-225. doi: 10.1016/j.jana.2016.06.001. Epub 2016 Jun 8.

PMID:
27396017
12.

MpUL-multi: Software for Calculation of Amyloid Fibril Mass per Unit Length from TB-TEM Images.

Iadanza MG, Jackson MP, Radford SE, Ranson NA.

Sci Rep. 2016 Feb 12;6:21078. doi: 10.1038/srep21078.

13.

An in vivo platform for identifying inhibitors of protein aggregation.

Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE.

Nat Chem Biol. 2016 Feb;12(2):94-101. doi: 10.1038/nchembio.1988. Epub 2015 Dec 14.

14.

β2-microglobulin amyloid fibrils are nanoparticles that disrupt lysosomal membrane protein trafficking and inhibit protein degradation by lysosomes.

Jakhria T, Hellewell AL, Porter MY, Jackson MP, Tipping KW, Xue WF, Radford SE, Hewitt EW.

J Biol Chem. 2014 Dec 26;289(52):35781-94. doi: 10.1074/jbc.M114.586222. Epub 2014 Nov 5.

15.

Synthesis and evaluation of 1-amino-6-halo-β-carbolines as antimalarial and antiprion agents.

Thompson MJ, Louth JC, Little SM, Jackson MP, Boursereau Y, Chen B, Coldham I.

ChemMedChem. 2012 Apr;7(4):578-86. doi: 10.1002/cmdc.201200002. Epub 2012 Jan 24.

PMID:
22275299
16.

Mid-term results of third-generation alumina-on-alumina ceramic bearings in cementless total hip arthroplasty: a ten-year minimum follow-up.

Yeung E, Bott PT, Chana R, Jackson MP, Holloway I, Walter WL, Zicat BA, Walter WK.

J Bone Joint Surg Am. 2012 Jan 18;94(2):138-44. doi: 10.2106/JBJS.J.00331.

PMID:
22258000
17.

Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity.

Thompson MJ, Louth JC, Ferrara S, Jackson MP, Sorrell FJ, Cochrane EJ, Gever J, Baxendale S, Silber BM, Roehl HH, Chen B.

Eur J Med Chem. 2011 Sep;46(9):4125-32. doi: 10.1016/j.ejmech.2011.06.013. Epub 2011 Jun 17.

PMID:
21726921
18.

The role of patient factors and implant position in squeaking of ceramic-on-ceramic total hip replacements.

Sexton SA, Yeung E, Jackson MP, Rajaratnam S, Martell JM, Walter WL, Zicat BA, Walter WK.

J Bone Joint Surg Br. 2011 Apr;93(4):439-42. doi: 10.1302/0301-620X.93B4.25707.

PMID:
21464479
19.

Immobilization and molecular interactions between bacteriophage and lipopolysaccharide bilayers.

Handa H, Gurczynski S, Jackson MP, Mao G.

Langmuir. 2010 Jul 20;26(14):12095-103. doi: 10.1021/la1013413.

PMID:
20481467
20.

Timing of reconstruction of the anterior cruciate ligament in athletes and the incidence of secondary pathology within the knee.

Kennedy J, Jackson MP, O'Kelly P, Moran R.

J Bone Joint Surg Br. 2010 Mar;92(3):362-6. doi: 10.1302/0301-620X.92B3.22424.

PMID:
20190306
21.

Ceramic-on-ceramic bearing surface and risk of revision due to dislocation after primary total hip replacement.

Sexton SA, Walter WL, Jackson MP, De Steiger R, Stanford T.

J Bone Joint Surg Br. 2009 Nov;91(11):1448-53. doi: 10.1302/0301-620X.91B11.22100.

PMID:
19880888
22.

The effect of obesity on the mid-term survival and clinical outcome of cementless total hip replacement.

Jackson MP, Sexton SA, Yeung E, Walter WL, Walter WK, Zicat BA.

J Bone Joint Surg Br. 2009 Oct;91(10):1296-300. doi: 10.1302/0301-620X.91B10.22544.

PMID:
19794162
23.

The impact of obesity on the mid-term outcome of cementless total knee replacement.

Jackson MP, Sexton SA, Walter WL, Walter WK, Zicat BA.

J Bone Joint Surg Br. 2009 Aug;91(8):1044-8. doi: 10.1302/0301-620X.91B8.22129.

PMID:
19651831
24.

Recognition of Salmonella Typhimurium by Immobilized Phage P22 Monolayers.

Handa H, Gurczynski S, Jackson MP, Auner G, Mao G.

Surf Sci. 2008 Apr 1;602(7):1392-1400.

25.

Three Tesla MRI for the diagnosis of meniscal and anterior cruciate ligament pathology: a comparison to arthroscopic findings.

Sampson MJ, Jackson MP, Moran CJ, Shine S, Moran R, Eustace SJ.

Clin Radiol. 2008 Oct;63(10):1106-11. doi: 10.1016/j.crad.2008.04.008. Epub 2008 Jun 16. Erratum in: Clin Radiol. 2009 Jul;64(7):747.

PMID:
18774357
26.

Supracondylar periprosthetic femoral fractures following total knee arthroplasty: treatment with a retrograde intramedullary nail.

Chettiar K, Jackson MP, Brewin J, Dass D, Butler-Manuel PA.

Int Orthop. 2009 Aug;33(4):981-5. doi: 10.1007/s00264-008-0587-y. Epub 2008 Jun 6.

27.

Medial tibial plateau fracture complicating unicompartmental knee arthroplasty.

Rudol G, Jackson MP, James SE.

J Arthroplasty. 2007 Jan;22(1):148-50. Epub 2006 Apr 17.

PMID:
17197324
28.

High frequency oscillatory ventilation successfully used to treat a severe paediatric inhalation injury.

Jackson MP, Philp B, Murdoch LJ, Powell BW.

Burns. 2002 Aug;28(5):509-11. No abstract available.

PMID:
12163295
29.

Morphew, leprosy, and the date of Marston's Antonio and Mellida.

Neill M, Jackson MP.

Notes Queries. 1998 Sep;45(3):358-60. No abstract available.

PMID:
11620553
30.

Inhibition of prokaryotic translation by the Shiga toxin enzymatic subunit.

Skinner LM, Jackson MP.

Microb Pathog. 1998 Feb;24(2):117-22.

PMID:
9480794
31.
33.
34.

Analysis of Shiga toxin subunit association by using hybrid A polypeptides and site-specific mutagenesis.

Jemal C, Haddad JE, Begum D, Jackson MP.

J Bacteriol. 1995 Jun;177(11):3128-32.

35.

Cytotoxicity of a shiga toxin A subunit-CD4 fusion protein to human immunodeficiency virus-infected cells.

al-Jaufy AY, Haddad JE, King SR, McPhee RA, Jackson MP.

Infect Immun. 1994 Mar;62(3):956-60.

37.
38.

Minimum domain of the Shiga toxin A subunit required for enzymatic activity.

Haddad JE, al-Jaufy AY, Jackson MP.

J Bacteriol. 1993 Aug;175(16):4970-8.

39.
40.
41.

Homelessness as a determinant of health.

Jackson MP, McSwane DZ.

Public Health Nurs. 1992 Sep;9(3):185-92.

PMID:
1409346
43.

Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis.

O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT.

Curr Top Microbiol Immunol. 1992;180:65-94. Review. No abstract available.

PMID:
1324134
45.

Transcription of the Shiga-like toxin type II and Shiga-like toxin type II variant operons of Escherichia coli.

Sung LM, Jackson MP, O'Brien AD, Holmes RK.

J Bacteriol. 1990 Nov;172(11):6386-95.

46.

Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits.

Jackson MP, Deresiewicz RL, Calderwood SB.

J Bacteriol. 1990 Jun;172(6):3346-50.

47.

Structure-function analyses of Shiga toxin and the Shiga-like toxins.

Jackson MP.

Microb Pathog. 1990 Apr;8(4):235-42. Review. No abstract available.

PMID:
2200941
48.

Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis.

Jackson MP, Wadolkowski EA, Weinstein DL, Holmes RK, O'Brien AD.

J Bacteriol. 1990 Feb;172(2):653-8.

49.
50.

Supplemental Content

Loading ...
Support Center